Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

 
• By Joseph Haas
FDA approved
Karyopharm's accelerated approval now awaits confirmatory Phase III data

More from New Products

More from Scrip